ARTICLE | Product Development
Roche reveals trial failures
April 23, 2020 1:31 AM UTC
Along with its 1Q20 earnings, Roche disclosed negative readouts in three clinical trials.
Following a futility analysis, Roche (SIX:ROG; OTCQX:RHHBY) stopped the Phase III V1aduct trial of V1a receptor antagonist balovaptan (RG7314) to treat adults with autism; a Phase II pediatric study is ongoing. ...